Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population

On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for lower respiratory tract disease (LRTD).

The data show that the vaccine has the potential to help protect a broader group of adults at risk from the potentially serious consequences of RSV.

In the U.S. alone, the number of adults aged 18-49 with at least one risk factor that could put them at risk for RSV disease could exceed 21 million.

Also Read: GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations

The vaccine is currently approved for active immunization to prevent RSV-LRTD in adults aged 60 and older and in adults aged ...